Reneo Pharmaceuticals Inc., a company developing a PPAR delta agonist to treat genetically defined rare mitochondrial diseases, has completed a $50 million series A financing that it said will help support ongoing phase Ib trials of candidate REN-001, as well as other clinical and preclinical studies.